Sign up to save your podcasts
Or
Share The Lancet Respiratory Medicine: December 05, 2013
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Lancet Respiratory Medicine: December 05, 2013
Klaus Rabe discusses a study that looks at ADRB2 polymorphisms and drug efficacy in preventing COPD exacerbations in patients from the POET trial.
View all episodes
By The Lancet Respiratory MedicineKlaus Rabe discusses a study that looks at ADRB2 polymorphisms and drug efficacy in preventing COPD exacerbations in patients from the POET trial.